1. Medtech Insight
  2. >>Device Area
  3. >>Diabetic Care

Reapplix ‘Focused Exclusively’ On US Wound Patch Launch After Securing Reimbursement

 
• By Sten Stovall

Reapplix’s CEO tells Medtech Insight the Danish group now has the funds to launch its biological wound healing patch in the US for treating patients with diabetic foot ulcers.

Foot_Ulcer
Reapplix’s 3CPatch System repairs hard-to-heal diabetic foot ulcers. • Source: Shutterstock

Reapplix APS has postponed indefinitely plans to roll out its proprietary biological wound-healing patch in Europe for treating patients with diabetic foot ulcers due to uncertainty over product reimbursement there. It will instead focus exclusively on launching its 3CPatch in the US where it has its reimbursement rate and coding recently confirmed, the Danish group’s CEO said in an interview.

Reapplix’s path to commercializing its 3CPatch in the US opened up when the group received Medicare reimbursement coding instructions from...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Diabetic Care

Medtronic To Spin Out Diabetes Unit As New Products Solidify Turn-Around Story

 
• By Shubham Singh

Medtronic’s diabetes spin-out – a process likely to run up to 18 months and involve 20% IPO followed by a split-off for Medtronic shareholders – will allow firm to focus on higher-margin devices.

Abbott’s FreeStyle Libre CGM Reduces Cardiovascular Disease-Related Hospitalization

 
• By Natasha Barrow

The REFLECT studies showed a 78% reduction in cardiovascular disease-related hospitalization for people living with type 1 diabetes with prior low blood sugar episodes.

Roche To Localize CGM Manufacturing in US with $550M Indiana Site Investment

 
• By Shubham Singh

Roche’s Indianapolis site currently produces 5.2 billion Accu-Chek test strips annually and supports distribution to 53 countries. The new CGM line will add to an already diversified operational footprint, which includes R&D, laboratories, manufacturing, and IT services.

Consumer Healthtech Investment Totaled $4.5BN In 2024, But Bar Is High Amid Economic Uncertainty

 
• By Marion Webb

Global investment in consumer healthtech increased by 9% year-over-year in 2024, totaling $4.5bn, with significant interest in mental health solutions, according to Galen Growth. While the first quarter of 2025 saw raised confidence and investments, the Trump administration’s new tariffs and sweeping changes to healthcare have introduced new uncertainties.

More from Device Area

J&J MedTech Launches KINCISE 2 Surgical Automated System In US

 
• By Natasha Barrow

The KINCISE 2 Surgical Automated System aims to “reduce the physical burden on surgeons compared to manual impaction in primary and revision hip and revision knee replacement procedures,” said J&J MedTech.

Abbott Launches Next-Gen Delivery System For Proclaim DRG Neurostim

 
• By Shubham Singh

Allen Burton, Abbott’s medical director of neuromodulation told Medtech Insight that the delivery system was developed to make the procedure easier for physicians, especially those who perform the implantations infrequently.

Digital Health Roundup: Synchron Syncs With Apple, Ketryx’s AI Agents, AdvaMed’s AI RoadMap

 
• By Marion Webb, Brian Bossetta, Natasha Barrow, Elizabeth Orr, and Shubham Singh

In this week's Digital Health Roundup, MedTech Insight's Shubham Singh explores how Ketryx's launch of validated AI agents could reshape compliance automation in medtech. Marion Webb highlights news from BCI makers Synchron, Axoft and Subsense. Elizabeth Orr discusses AI advances at the FDA.